In contrast to the initial notion that the biological activity of p14
Introduction

P14
ARF (p19 ARF in the mouse) was originally identified as the alternative transcript of the human INK4a tumor suppressor locus, which also encodes the cdk inhibitor p16
INK4a (Mao et al., 1995; Quelle et al., 1995) . Although sharing exons 2 and 3, p14 ARF and p16 INK4a are structurally and functionally completely unrelated, as transcription of p14 ARF initiates at a separate exon 1b and proceeds in an alternative reading frame (ARF). By linking the Rb and p53 signaling pathways, ARF plays a central role in monitoring cellular proliferation (Lowe and Sherr, 2003) . Usually expressed at hardly detectable levels, p14
ARF is rapidly upregulated upon expression of viral and cellular oncogenes (de Stanchina et al., 1998; Palmero et al., 1998; Zindy et al., 1998) . Through physical stabilization of p53 via sequestration and subsequent proteasomal degradation of mdm-2 (Hdm-2 in humans), p14
ARF was shown to trigger the transcription and activity of p53-responsive genes such as p21 or bax (Stott et al., 1998; Weber et al., 1999) . Therefore, it was suggested that p14 ARF primarily utilizes the mdm-2/p53 signaling axis (Sharpless and DePinho, 1999; Sherr, 2001) . However, the tumor susceptibility of triple knockout mice lacking p19 ARF , p53 and mdm-2 turned out to be higher as compared to mice lacking any of these genes alone . Consequently, a number of follow-up studies demonstrated that p14 ARF is capable of affecting both cell cycle control and apoptosis induction in a p53-independent manner as well (Hemmati et al., 2002; Korgaonkar et al., 2002; Yarbrough et al., 2002; Eymin et al., 2003; Rocha et al., 2003; Qi et al., 2004; Hemmati et al., 2005; Normand et al., 2005) . Recently, ARF-BP1/mule, an E3 ubiquitin ligase, has been identified as a critical component of the ARF tumor suppressor pathway, as it mediates at least part of the mdm-2/p53-independent regulation of apoptosis sensitivity (Chen et al., 2005a; Zhong et al., 2005) . Taken together, these data indicate the INK4a/ARF tumor suppressor pathway involves a much more complex signaling network than initially thought Shmueli and Oren, 2005) and further challenge the paradigm that ARF signaling strictly depends on a functional mdm-2/p53 rheostat.
Extrinsic and intrinsic apoptosis pathways converge at the level of mitochondria, which, therefore, serve as central integrators within the apoptotis machinery . In mammals, the activation of mitochondria, that is breakdown of the mitochondrial membrane, critically depends on Bax and its homolog Bak, two proapoptotic members of the Bcl-2 family (Lindsten et al., 2000) . Upon appropiate stimuli, Bax undergoes an N-terminal conformational change and translocates to the outer mitochondrial membrane where it oligomerizes and forms pores, which allow for the release of cytochrome c and other factors such as Smac/DIABLO. These events are followed by the formation of the mitochondrial apoptosome and subsequent execution of apoptosis. In contrast to Bax, the role of Bak in mitochondrial apoptosis is less well understood. Whereas Bax is primarily localized in the cytosol, Bak is permanently embedded into the outer mitochondrial membrane. Similar to Bax, the activation of Bak involves an N-terminal conformational change and oligomerization. Most studies addressing the impact of Bax and Bak on apoptosis sensitivity of cancer cells therefore suggest that both proteins are partially redundant. Nevertheless, recent evidence delineates that Bax and Bak exert also nonredundant activities Cartron et al., 2003; Gillissen et al., 2003; von Haefen et al., 2004; Wendt et al., 2005) . At the molecular level, this may be reflected by the fact that Bax and Bak are differentially controlled by additional factors such as VDAC2 (Cheng et al., 2003; Chandra et al., 2005) . Furthermore, the proapoptotic activity of Bax and Bak is hold in check by distinct antiapoptotic Bcl-2 family members. Finally, BH3-only proteins have recently been shown to preferentially activate either Bax-or Bak-dependent events in human cells Gillissen et al., 2003; Yu et al., 2003; Willis et al., 2005) .
We recently showed that the induction of mitochondrial apoptosis by p14 ARF is independent of p53 and Bax and can be further enhanced by loss of p21 in p53-proficient cells (Hemmati et al., 2002; Hemmati et al., 2005) . However, the role of Bak during p14 ARF -induced apoptosis in cells either proficient or deficient for p53 remains unclear. Notably, p14 ARF -induced apoptosis in p53/p21-deficient DU145 cells is fully independent of Bax indicating that mechanisms other than simply triggering the p53/Bax cascade are involved in mitochondrial apoptosis induction. We show here in p53 wild-type HCT116 cells that Bak almost fully rescues for the loss of Bax during p14 ARF -induced mitochondrial apoptosis by p14 ARF . Consequently, the combined loss of both Bax and Bak severely impairs, although not entirely abrogates, apoptosis sensitivity in p53 wild-type HCT116 cells upon p14 ARF expression. Nevertheless, a significant proportion of cell death proceeds via a Bax/Bakindependent pathway. This is also the case for inhibition of clonogenic growth that was abrogated completely by p14 ARF regardless of Bax/Bak expression in the HCT116 system.
Results
Induction of cell cycle arrest in G1 phase by p14 ARF strictly depends on the presence of both p53 and p21 . Nevertheless, in cells deficient for p53, p21 or both, p14
ARF triggers a G2 cell cycle arrest, which is mediated by downregulation of p34 cdc2 (cdk-1) kinase activity (Eymin et al., 2003; Normand et al., 2005) . This is in contrast to the initial idea that both apoptosis induction and cell cycle arrest by p14 ARF strictly depend on a functional mdm-2/p53/p21 signaling axis (Sherr, 2001) . Furthermore, we showed that p14 ARF triggers the mitochondrial apoptosis pathway in cancer cells deficient for both p53 and Bax (Hemmati et al., 2002) . Moreover, loss of p21 strongly enhanced p14 ARF -induced apoptotic cell death . Taken together, these data further underline the notion that p14
ARF induces a broad spectrum of mdm-2/ p53/p21-independent effects (Groth et al., 2000; Eymin et al., 2001; Fatyol and Szalay, 2001; Korgaonkar et al., 2002; Yarbrough et al., 2002; Qi et al., 2004) but, nevertheless, point out that the signaling events controlling cell cycle arrest and apoptosis induction by p14 ARF are closely interconnected (Sherr, 2004) .
-induced apoptosis is Bax independent in p53/Bax-deficient DU145 cells We previously reported that p14
ARF induces p53/Baxindependent apoptosis (Hemmati et al., 2002; Hemmati et al., 2005) . To corroborate the impact of Bax reexpression in p53/Bax-deficient DU145 prostate cancer cells, we tested a panel of mock-and Bax-transfected stable clones (Gillissen et al., 2003) and studied caspase activation, cytochrome c release and dissipation of the mitochondrial membrane potential. To this end, DU145 cells either deficient (clones mock #2 and mock #4) or reconstituted for Bax (clones bax #3 and bax #10) were infected with an increasing multiplicity of infection (m.o.i.) of Ad-p14 ARF or a control vector (Ad-lacZ; 100 m.o.i.) or were mock treated. As expected, p14 ARF induced a dose-dependent increase in apoptotic DNA fragmentation ( Figure 1a ) and pan-caspase activities (Figure 1b ) 72 h after infection. Notably, there was no significant difference between clones either deficient or proficient for Bax. However, re-expression of the bax-a cDNA sensitized markedly for apoptotic DNA fragmentation ( Figure 1c ) and pan-caspase activation (Figure 1d ) following exposure to the topoisomerase IIa poison epirubicin. As expected, p14 ARF failed to induce the expression of p53 and p21 in p53-mutated DU145 cells, confirming that DU145 carries a p53 lossof-function mutation (Figure 1e ). Despite expressing different levels of Bax, all clones exhibited apoptotic DNA fragmentation and pan-caspase activation to a similar extent upon treatment with epirubicin. This suggests that low levels of Bax are sufficient to mediate epirubicin-induced mitochondrial membrane potential loss, caspase activation and apoptotic cell death. Moreover, we did not detect any marked difference in the expression of other anti-or proapoptotic Bcl-2 homologs such as Bcl-x S (absent; data not shown), Bcl-x L or Bcl-2 itself. This corroborates that apoptosis induction by p14 ARF in p53/p21-deficient DU145 cells is fully independent of loss of Bax and, furthermore, suggests that p14 ARF and epirubicin utilize distinct pathways for execution of apoptotic cell death.
Apoptosis induction by p14
ARF in p53/Bax-deficient DU145 cells involves the activation of mitochondria Apoptosis induction by p14 ARF in p53/Bax-mutated DU145 cells is independent of Bax. However, DU145 are wild type for Bak (Gillissen et al., 2003) , which may functionally rescue for Bax deficiency during the activation of mitochondria and subsequent activation of caspases, that is, caspase-9 and caspase-3/7. Therefore, we studied the capacity of p14 ARF to induce caspase-9-like (LEHDase) and caspase-3 ARF expression (Figure 2e ). Taken together, these data suggest that in DU145 cells lacking functional p53, p14 ARF -induced apoptosis involves the activation of mitochondria, which proceeds via Bak both in the absence or presence of Bax. Thus, in the absence of p53 and Bax, Bak is entirely sufficient to mediate p14 ARFdriven activation of the mitochondrial apoptosis pathway, that is to induce the release of cytochrome c, which is followed by caspase activation. ARF -induced mitochondrial apoptosis with regard to p53 proficiency versus p53 deficiency, we employed an shRNA approach for the stable knockdown of bak in p53-proficient HCT116 colon cancer cells either wild type (HCT116-Bax þ ) or homozygously deleted for the bax gene (HCT116-BaxÀ), thereby generating the four sublines HCT116-Bax þ /Bak þ , HCT116-BaxÀ/Bak þ , HCT116-Bax þ /BakÀ and HCT116-BaxÀ/BakÀ. As shown in Figure 3a (Bax þ /BakÀ) compared with wild-type cells (Bax þ / Bak þ ) at 72 h after infection, as evidenced by flow cytometric detection of fragmented nuclear DNA. In contrast, apoptotic DNA fragmentation upon expression of p14 ARF was substantially reduced in cells deficient for both Bax and Bak (BaxÀ/BakÀ). In all HCT116 sublines, p14 ARF -induced apoptosis was completely inhibited by the broad-spectrum caspase inhibitor zVADfmk (40 mM). As expected, apoptosis induction by epirubicin (2 mg/ml), which was used as a positive control, was strongly attenuated upon loss of Bax. In contrast, knockdown of Bak did not significantly affect . In turn, the combined loss of both Bax and Bak substantially impairs sensitivity towards p14 ARFmediated apoptosis. Nonetheless, a substantial part of p14 ARF -induced apoptosis occurs in a Bax/Bak-independent manner.
As expected, Western blot analysis revealed an increase in both p53 and p21 protein expression 48 h upon p14
ARF expression in all HCT116 sublines inves- It is noteworthy that a faint increase in Bak protein levels was detectable in Bax þ /BakÀ cells, which reached the background expression levels in Bax þ / Bak þ or BaxÀ/Bak þ cells, whereas BaxÀ/BakÀ cells remained void of Bak protein expression under conditions of p14 ARF expression. There was no difference in the expression levels of antiapoptotic Bcl-2 family members such as Bcl-x L and Bcl-2 among the four sublines. In parallel to the substantial reduction in apoptosis sensitivity, HCT116 cells deficient for both Bax and Bak (BaxÀ/BakÀ) lacked release of cytochrome c upon adenovirus-mediated p14 ARF expression (50 m.o.i.) as compared to Bax þ /Bak þ , Bax þ /BakÀ or BaxÀ/Bak þ HCT116 cells (Figure 4b ). In sum, these data indicate that apoptosis induction by p14 ARF involves the mitochondrial pathway, which is entirely impaired for cytochrome c release in the absence of both Bax and Bak. Thus, Bak functionally compensates for the loss of Bax and vice versa during p14 ARF -triggered mitochondrial apoptosis. Furthermore, these data indirectly indicate that Bax/Bak-independent apoptosis might occur through a distinct pathway that does not rely on cytochrome c release from mitochondria. ARF and subjected to flow cytometric analysis of pan-caspase activation by the use of a fluorescein isothiocyanate (FITC)-labeled derivative of the pancaspase inhibitor zVADfmk, which irreversibly binds to activated caspases in situ. As shown in Figure 5a and b, expression of p14 ARF induced a strong increase in pancaspase activities in HCT116 cells proficient for either Bax, Bak or both after 72 h. In contrast, pan-caspase activation was substantially reduced in HCT116 cells void of both Bax and Bak expression (BaxÀ/BakÀ). As expected, p14
ARF -triggered pan-caspase activities were strongly inhibited to background levels by the use of the pan-caspase inhibitor zVADfmk (40 mM). Similar to DNA fragmentation, p14 ARF -triggered caspase activities increased in a dose-dependent manner (Figure 5c ) reaching substantial levels as early as 48 h after infection with 50 m.o.i. Ad-p14 ARF (Figure 5d ). In sum, these data indicate that p14 ARF -induced mitochondrial apoptosis depends on either Bax or Bak and is preceded by the activation of caspases. In analogy to DNA fragmentation, pan-caspase activation by p14 ARF is most effective when both functional Bax and Bak are present.
Induction of mitochondrial apoptosis by p14
ARF involves Bax/Bak-dependent caspase-9-and caspase-3/7-like activities Apoptosis induction by p14 ARF involves the breakdown of the mitochondrial membrane potential (Hemmati et al., 2002) , which critically depends on the presence of either Bax or Bak to induce the release of cytochrome c before caspase activation. Therefore, we next assessed the impact of the loss of Bax, Bak or both on the ability of p14 ARF to induce caspase-9-like (LEHDase) activities. To this end, HCT116 cells were infected with 50 m.o.i. of Ad-p14 ARF and assayed for caspase-9-like activities by flow cytometry using the fluorescein-labeled caspase-9 substrate FAM-LEHDfmk (Figure 6a and b) . As expected, the sole loss of Bax (BaxÀ/Bak þ ) or Bak (Bax þ / BakÀ) only slightly affected caspase-9-like activities after 72 h as compared to Bax þ /Bak þ HCT116 cells. However, the combined loss of Bax and Bak in HCT116 cells (BaxÀ/BakÀ) resulted in a substantial reduction of caspase-9-like activities. As expected from previous experiments, caspase-9-like activities were induced by p14 ARF in a dose-dependent manner (Figure 6c ). In analogy to the release of cytochrome c with a subsequent increase of caspase-9-like LEHDase acti- ARF -triggered caspase-3/7-like activities were dose dependent (Figure 7c) . Notably, the overall extent of caspase-3/7-like activities is superior to caspase-9-like activities upon expression of p14 ARF , indicating that caspase-3/7 activation does not fully depend on the prior triggering of caspase-9. These results underline the notion that Bax and Bak are indispensable for full caspase activation during p14 ARFinduced mitochondrial apoptosis. Loss of Bax was again almost completely, although not fully, rescued by Bak and vice versa. 
Discussion
The p14 ARF tumor suppressor pathway encompasses a network of signaling events that is much more complex than previously suggested. In contrast to the initial notion that p14 ARF (and its murine homolog p19 ARF ) solely triggers an mdm-2/p53 signaling axis, we and others demonstrated that p14 ARF affects proliferation, that is, the induction of arrest in S and G2 phases of the cell cycle (Eymin et al., 2001; Yarbrough et al., 2002; Eymin et al., 2003; Hemmati et al., 2005; Normand et al., 2005) or the cell's response to DNA damage , in an entirely mdm-2/p53-independent manner. In the same vein, we previously showed that p14 ARF triggers mitochondrial apoptosis in cells deficient for p53 and Bax (Hemmati et al., 2002) . Nonetheless, p14 ARF -induced apoptosis was efficiently inhibited by antiapoptotic Bcl-x L , indicating that factors additional to Bax are involved in the control of mitochondrial sensitivity during apoptosis induction by p14 ARF . To further dissect the mechanism of p14 ARF -induced mitochondrial apoptosis, we analysed the role of Bak, a proapoptotic homolog of Bax, in cancer cells either proficient or deficient for functional p53.
To this end, we first re-addressed apoptosis signaling in the DU145 system and focussed on the role of Bax to trigger cytochrome c release and induction of caspase-9-and caspase-3/7-like activities following expression of p14 ARF . Consistent with previous data from our group, we show here that p14 ARF triggers the induction of caspase-9-like (LEHDase) and caspase-3/ 7-like (DEVDase) activities, which were, as expected, completely independent of the presence or absence of Bax. In the same vein, the p14 ARF -mediated breakdown of the mitochondrial membrane potential (DC m ) and release of cytochrome c did not differ between Baxproficient and Bax-deficient cells indicating that the activation of mitochondria following expression of p14 ARF does not rely on the presence of Bax. In striking contrast, epirubicin-induced apoptotic DNA fragmentation and pan-caspase activation were superior in Baxproficient DU145 cells as compared with Bax-deficient DU145 cells, indicating that drug-induced apoptosis is mediated mainly by Bax-induced activation of the mitochondrial apoptosis pathway in this system. Latter, as evidenced by DC m dissipation, correlates well with Bax protein expression levels, which differ between the two Bax-re-expressing DU145 clones #3 and #10. However, DU145 cells express Bak, which may well compensate for the loss of Bax expression in Baxmutant DU145 cells during activation of mitochondria and subsequent induction of apoptosis by p14 ARF . In fact, p14
ARF triggers a Bak-dependent pathway in p53-proficient HCT116 cells. This indicates that, in p53-deficient DU145 cells, p14 ARF triggers a mitochondrial apoptosis pathway that predominantly depends on Bak but not Bax. The underlying reason for this could reside in antiapoptotic Bcl-2 family members other than Bcl-2 and Bcl-x L that might be critical in regulating mitochondrial apoptosis sensitivity of DU145 cells as compared to other cells systems, that is, HCT116 cells. Moreover, the fact that DU145 cells are void of functional p53, which may translate into a failure of DU145 cells to upregulate certain BH3-only proteins during p14 ARF -induced apoptosis must be put into account. There is in fact evidence for such differential regulation of Bax and Bak by BH3-only proteins (Gillissen et al., 2003; Yu et al., 2003) . In turn, this may have profound effects on the apoptosis sensitivity of p53-deficient cells in general and, at the same time, alter the selectivity of certain apoptotic stimuli for Baxindependent versus Bax-dependent pathways of mitochondrial activation. Intriguingly, recent data indicate that antiapoptotic Bcl-2 family members distinctly control the proapoptotic activity of Bax or Bak (Chen et al., 2005b; Gelinas and White, 2005 (Willis et al., 2005) . These proteins appear to play selective roles, which may delineate a higher degree of specificity to the regulation of Bax and Bak in p14 ARF -induced cell death in analogy to other apoptosis-promoting stimuli (Theodorakis et al., 2002; Gillissen et al., 2003; Yu et al., 2003; von Haefen et al., 2004; Wendt et al., 2005) , which clearly demands further investigation.
In another recently published report, apoptosis induction by murine p19 ARF in mouse embryonic fibroblasts (MEFs) was shown to depend on Bax but not Bak and was subject to inhibition by Bcl-x L (Suzuki et al., 2003) . In the same vein, we observed that the forced expression of human p14 ARF by the use of an adenoviral expression system induces apoptosis in these cells in an entirely Bax, but not Bak-dependent manner (data not shown). However, as compared to human cancer cells derived from adult organisms, MEFs behave differently in many aspects, not only regarding apoptotic programs. In contrast to this report and our own data, neither apoptotic DNA fragmentation nor caspase activation upon expression by p14 ARF was dependent on or was sensitized for by reconstitution of Bax in p53/Bax-mutated human DU145 carcinoma cells. This was rather surprising, especially in view of the fact that disruption of p53 and Rb function by the SV40 large T-antigen in MEFs should result in a genotype that mimics DU145 cells, which are also p53 and Rb mutated. The molecular mechanisms of this apparent discrepancy between murine embryonic cells and human adult cancer cells remain so far enigmatic, but might well reside in a distinct expression profile of antiapoptotic Bcl-2 homologs and in the induction of BH3-only proteins by ARF.
Based on these findings, we aimed at further defining the role of Bak, in particular in relation to the presence or absence of functional p53, during p14 ARF -induced apoptosis. Using an isogeneic model system, that is, the shRNA-mediated knockdown of Bak in p53-wild-type HCT116 cells either proficient or deficient for Bax, we show that Bak is effective in the substitution for loss of Bax and vice versa during p14 ARF -induced apoptosis. Notably, Bak was equally effective as compared to Bax in mediating p14 ARF -induced activation of mitochondria, caspase activation and subsequent fragmentation of genomic DNA. The critical role of both Bak and Bax during apoptosis induction by p14 ARF is further underlined by the observation that their combined loss completely impaired mitochondrial activation, as evidenced by the failure of Bax/Bak double-deficient cells to release cytochrome c upon p14
ARF expression. This is in clear contrast to other proapoptotic stimuli, that is, death receptor ligands such as TRAIL (von Haefen et al., 2004; Wendt et al., 2005) or the BH3-only proteins Nbk (Gillissen et al., 2003) or Puma (Yu et al., 2003) that completely rely on the presence of Bax, but not Bak, to facilitate the activation of mitochondria and subsequent execution of apoptotic cell death in human cancer cells. Consequently, we observed that epirubicininduced apoptosis occurred in a predominantly Baxdependent manner in our systems. Is is noteworthy that this indicates that p14 ARF , in contrast to other stimuli, utilizes a distinct pathway to trigger the activation of mitochondria.
Although Bak can functionally substitute for the loss of Bax and vice versa, p14 ARF -induced mitochondrial apoptosis was most effective in the presence of both Bax and Bak in p53-proficient cells. In turn, the single loss of either Bax or Bak had a slight, but consistent effect on apoptotis sensitivity upon expression of p14 ARF . This is in line with the observation that in p53 wild-type cells, p14 ARF induces p53 target gene expression, that is, bax and bak among others, as observed in the present context observed in the HCT116 system. In turn, this indicates that p14 ARF -triggered mitochondrial apoptosis depends to a large extent on Bax and/or Bak in p53 wild-type cells. Therefore, our data are in full agreement with a number of previous studies, showing that p14 ARF induces p53-dependent signaling events (Sherr, 2001) .
Although severely impaired, the combined loss of Bax and Bak was not sufficient to completely inhibit the induction of cell death by p14
ARF . This suggests that part of p14 ARF -induced apoptosis relies on Bax-and Bakindependent events although loss of both Bax and Bak completely abrogates cytochrome c release induced by p14 ARF . This Bax/Bak-independent apoptosis signaling should therefore be mediated through cellular compartments distinct from the mitochondria. The Bax/Bak homolog Bok/Mtd may represent one putative candidate in this setting. Although shown to be mostly restricted to cells from reproductive tissues, a recent study demonstrated that Bok/Mtd is capable of substituting for the loss of Bax during DNA-damageinduced apoptosis in cancer cells of neuronal and epithelial origin, respectively (Yakovlev et al., 2004) . Notably, pan-caspase inhibition by the use of zVADfmk almost completely inhibited p14 ARF -induced cell death, indicating an apoptotic mode of cell death execution. This is a relevant point, as recent data on drug-and oncogene-induced cell death propagate a concept of non-apoptotic cell death, that is, by regulated necrosis or autophagy (Zong et al., 2004; Scholz et al., 2005a, b) . This does, however, not appear to be the case in the present setting of p14 ARF -induced apoptosis. The functional relevance of this Bax/Bak-independent pathway of cell death execution is underlined by the analysis of clonogenic survival and growth in Bax/Bakproficient or -deficient cells. There, the combined loss of both Bax and Bak expression failed to facilitate clonogenic survival following forced expression of p14 ARF . Although induction of cell cycle arrest and/or cellular senescence contributes to inhibition of clonogenic growth, these data suggest that cell death signaling events other than the simple triggering of the p53/ Bax-Bak apoptotic signaling cascade are critically involved in the cellular response to p14 ARF expression (Figure 9 ).
Materials and methods
Cell culture HEK293 and DU145 were obtained from the ATCC (Manassas, VA, USA) or the DSMZ (Braunschweig, Germany) and grown in Dulbecco's modified Eagle medium (DMEM)/high-glucose (4.5 g/l) medium (Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin and 0.1 mg/ml streptomycin (all from Invitrogen). Bax-reconstituted DU145 cells were generated as described earlier (Hemmati et al., 2002; Gillissen et al., 2003) . HCT116 wild-type cells proficient for Bax and Bak (Bax þ /Bak þ ) and their isogeneic knockout subline HCT116-BaxKO (BaxÀ/Bak þ ) (Zhang et al., 2000) were generously provided by Dr Bert Vogelstein (Johns Hopkins Cancer Center, Baltimore, USA). The stable knockdown of Bak was performed in either HCT116 wild-type and HCT116-BaxKO cells by the use of a small hairpin (sh) RNA based on the pSUPER vector yielding Bax þ /BakÀ and BaxÀ/BakÀ cells (Theodorakis et al., 2002) . All HCT116 sublines were cultured in McCoy's 5A medium supplemented with 10% FCS, 100 U/ml penicillin and 0.1 mg/ml streptomycin.
Construction of recombinant Ad5-CMVp14
ARF Recombinant, replication-deficient Ad5-CMVp14 ARF (Adp14 ARF ) was constructed as described (Hemmati et al., 2002) and high-titer stocks of recombinant adenovirus were generated following standard procedures (Gillissen et al., 2003) . An adenoviral vector expressing b-galactosidase (Ad-lacZ) was used as a control. Cells were maintained at 371C with 5% CO 2 in a fully humidified atmosphere and infected with adenoviral vectors in DMEM/high glucose in the absence of FCS or antibiotics for 2 h at 371C. Thereafter, DMEM/high glucose supplemented with 20% FCS, 200 U/ml penicillin and 0.2 mg/ml streptomycin was added. Cells were mocktreated with serum-free medium in parallel.
Antibodies and reagents
Mouse monoclonal anti-p14 ARF antibody (clone 14P02, raised against full-length recombinant human p14 ARF ) was purchased from NeoMarkers (Fremont, CA, USA) and used at a dilution of 1:1000. Antibodies against p21 (clone 6B6, raised against a fusion protein between glutathione-S-transferase and fulllength human p21), p53 (clone DO-1, reactive against amino acids (aa) 1-45 of human p53) and cytochrome c (clone 7H8.2C12; raised against synthetic peptides corresponding to aa 1-80, 81-104 and 66-104 of pigeon cytochrome c) were murine monoclonal antibodies purchased from BD-Pharmingen (Heidelberg, Germany) used at a dilution of 1:1000. Rabbit polyclonal antibodies against Bcl-x (BD-Pharmingen; reactive against aa 46-66 of human Bcl-x) and actin (SigmaAldrich; St Louis, MI, USA; reactive against an 11-aa C-terminal actin fragment) were used at a dilution of 1:200. Anti-Bak (raised against a synthetic peptide corresponding to aa 16-34 of human Bak) was a rabbit polyclonal antibody from Dako Cytomation (Glostrup, Denmark) used at a dilution of 1:100. Anti-Bcl-2 (clone bcl-2/100/D5, raised against the synthetic peptide GAAPAPGIFSSQPGC) was a mouse monoclonal antibody purchased from Novocastra (Newcastle upon Tyne, UK) used at a dilution of 1:100. Anti-Bax (clone YTH-2D2; raised against a synthetic peptide corresponding to aa 3-16 of human Bax) was a mouse monoclonal from Trevigen (Gaithersburg, MD, USA) used at a dilution of 1:10 000. All antibodies were diluted in phosphate-buffered saline (PBS) supplemented with 0.05% Tween 20 (PBS-T), 4% non-fat dry milk and 0.1% NaN 3 . Secondary goat anti-mouse IgG and goat anti-rabbit IgG antisera coupled to horseradish peroxidase (HRP) were from Southern Biotechnology Associates (Birmingham, AL, USA) and used at a dilution of 1:10 000 in PBS-T.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis and Western blot analysis Cells were harvested by trypsinization, washed twice with icecold PBS and lysed in appropiate amounts of lysis buffer (10 mM Tris/HCl, pH 7.5, 300 mM NaCl, 1% Triton X-100, 2 mM MgCl 2 , 5 mM ethyleneidiamine-N,N,N,N-tetraacetic acid (EDTA)) supplemented with complete protease inhibitors (Roche, Mannheim, Germany) for 15 min on ice. Samples were then centrifuged at 15 000g for 15 min at 41C and the concentration of total cellullar proteins from the supernatants was determined using the bicinchoninic acid assay from Pierce (Rockford, IL, USA). Thereafter, samples were mixed with 5 Â sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (125 mM Tris/HCl, 288 mM bmercaptoethanol, 20% glycerol, 2% SDS, 10 mg/ml bromophenol blue) and boiled for 5 min. Equal amounts of protein (20 mg) were separated by SDS-PAGE using 16, 12 or 10% gels. Immunoblotting and visualization of the proteins using enhanced chemiluminescence were performed as described (Hemmati et al., 2002) . For control of equal protein loading, ARF induces caspase-3/7 activation in the absence of mitochondrial activation and/or trigering of caspase-9. Finally, nonapoptotic forms of cell death, that is, programmed necrosis or autophagy, could be engaged upon expression of p14 ARF . Activation of G1 cell cycle arrest and senescence strictly depends on the presence of p53 and p21. Regardless of p53/p21, p14 ARF retains its capacity to block G2/M cell cycle progression by downregulation of cdc2 (cdk-1).
membranes were re-probed with an antibody against actin (Sigma-Aldrich).
Detection of cytochrome c release Cytosolic extracts were prepared as described previously (von Haefen et al., 2003) . Briefly, cells were harvested by trypsinization, washed twice in ice-cold PBS and lysed in 40 ml of hypotonic buffer (20 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES), pH 7.4, 10 mM KCl, 2 mM MgCl 2 , 1 mM EDTA) supplemented with 1 mM PMSF and 0.75 mg/ml digitonin (Sigma-Aldrich). After incubation on ice for 3 min, debris was pelleted by centrifugation at 10 000g for 10 min at 41C. Thereafter, supernatants were transfered to a fresh tube, mixed with 10 ml of 5 Â SDS-PAGE sample buffer and boiled for 5 min. Equal amounts of protein (20 mg) were separated by SDS-PAGE using 16% gels and subjected to Western blot analysis as described above.
Measurement of apoptotic cell death
Apoptotic DNA fragmentation was determined on a single cell level by measuring the DNA content of individual cells with a logarithmic amplification in the FL-3 channel of a FACScan flow cytometer (BD-Pharmingen) equipped with the CellQuestPro software as described (Hemmati et al., 2002) . Briefly, 1 Â 10 5 cells were infected with the indicated adenoviral vectors or mock treated. At the indicated time points, cells were trypsinized and collected by centrifugation at 300g for 5 min, washed once with PBS and fixed in PBS/2% (v/v) formaldehyde for 30 min on ice. Thereafter, cells were incubated in 70% ethanol/PBS (v/v) for 30 min on ice, pelleted and resuspended in PBS containing 40 mg/ml DNase-free RNase A (Roche Molecular Biochemicals, Mannheim, Germany). After incubation for 30 min at 371C, cells were pelleted again and resuspended in PBS containing 50 mg/ml propidium iodide (Sigma-Aldrich). Data are given in percent hypoploidy, that is, the percentage of cells with a sub-G1 DNA content, which reflects the percentage of apoptotic cells with fragmented genomic DNA.
Measurement of mitochondrial permeability transition (DC m )
Mitochondrial permeability transition was determined by the use of 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethyl-benzimidazolylcarbocyanin iodide (JC-1; Molecular Probes, Leiden, The Netherlands) as described (Gillissen et al., 2003) . Briefly, equal numbers of cells (1 Â 10 5 ) were incubated with JC-1 at 2.5 mg/ ml in 500 ml PBS for 30 min at 371C with moderate shaking. Cells were then centrifuged at 300g, 41C for 5 min, washed twice with ice-cold PBS and resuspended in 200 ml PBS. 
